Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643026 | 1.00 | ALOX15 (0.59) | ALOX15HSD17B10SIGMAR1SLC6A9CYP1A2 | |
| SCHEMBL34418 | 1.00 | ALOX15 (0.59) | ALOX15HSD17B10SIGMAR1SLC6A9CYP1A2 | |
| SCHEMBL30291153 | 1.00 | ALOX15 (0.59) | ALOX15HSD17B10SIGMAR1SLC6A9CYP1A2 | |
| SCHEMBL24709144 | 0.90 | ALOX15 (0.48) | ALOX15HSD17B10SIGMAR1SLC6A9CYP1A2 | |
| SCHEMBL8033814 | 0.87 | SMN1; SMN2 (0.47) | ALOX15HSD17B10SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL20366148 | 0.87 | SMN1; SMN2 (0.47) | ALOX15HSD17B10SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL8512446 | 0.87 | SMN1; SMN2 (0.47) | ALOX15HSD17B10SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL8742080 | 0.85 | HSD17B10 (0.62) | ALOX15HSD17B10SLC6A9CYP1A2MAPK1 | |
| SCHEMBL23646017 | 0.85 | HSD17B10 (0.62) | ALOX15HSD17B10SLC6A9CYP1A2MAPK1 | |
| SCHEMBL8510307 | 0.85 | SIGMAR1 (0.47) | ALOX15HSD17B10SIGMAR1CYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3206720-B1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2020-04-22 | — | — | EP | disclosed |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| EP-2300033-B1 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2016058704-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2016-04-21 | — | — | WO | disclosed |
| US-8575311-B2 | Collagen peptide conjugates and uses therefor | PURDUE RESEARCH FOUNDATION (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110081324-A1 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1637524-A1 | 10-substituted 1-, 4, 7,-tris (carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane derivative for use as contrast agents | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | PTH1R, VDR, MEN1 | ALOX15 4027/4885HSD17B10 3937/4885SIGMAR1 3668/4885 |
| US-20110081324-A1 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR | COL14A1, COL1A1, COL2A1 | ALOX15 1147/4885HSD17B10 3467/4885SIGMAR1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.